m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT02132
 [1], [2]
DNA methylation DNMT3A METTL3 Direct Inhibition m6A modification BCL2 BCL2 METTL3 Methylation : m6A sites
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Apoptosis regulator Bcl-2 (BCL2)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type DNA methylation (DNAMeth)
Epigenetic Regulator Cysteine methyltransferase DNMT3A (DNMT3A) WRITER View Details
Regulated Target Methyltransferase-like protein 3 (METTL3) View Details
Crosstalk Relationship DNA methylation  →  m6A Inhibition
Crosstalk Mechanism DNA methylation directly impacts m6A modification through modulating the expression level of m6A regulator
Crosstalk Summary Quantitative chromatin immunoprecipitation (ChIP) assays showed that CSC substantially reduced the bindings of DNA methyltransferase 1 (DNMT1) and DNMT3A to the METTL3 promoter. celastrol treatment downregulated METTL3 and decreased m6A levels of Claspin and Apoptosis regulator Bcl-2 (BCL2) mRNA, leading to the degradation of Claspin and Bcl-2 mRNA in pancreatic cancer cells. Furthermore, we revealed that celastrol treatment downregulated Claspin and Bcl-2, at least in part, in an m6A-YTHDF3-mediated manner in pancreatic cancer cells.
Responsed Disease Pancreatic cancer ICD-11: 2C10
 Disease Info 
Responsed Drug Celastrol
 Drug Info 
Pathway Response PI3K-Akt signaling pathway hsa04151
Cell Process Cell proliferation
In-vitro Model
 PANC-1 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0480
SW1990 Pancreatic adenocarcinoma Homo sapiens CVCL_1723
AsPC-1 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0152
BxPC-3 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0186
In-vivo Model Female BALB/c nude mice, aged 4-5 weeks, purchased from the Beijing Vital River Laboratory Animal Technology, were allowed to acclimate to local conditions for 1 week and maintained under a 12-h dark/12-h light cycle with food and water provided ad libitum. Mice (five in each group) were injected subcutaneously with 0.1 ml of cell suspension containing 2 × 106 cells in the back flank. When a tumor was palpable, it was measured every other day and the volume was calculated according to the formula volume = length × width2 × 0.5.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Apoptosis regulator Bcl-2 (BCL2) 49 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name GDC-0199 Approved [3]
MOA Modulator
Activity Ki < 0.01 nM
External Link
CID: 49846579
TTD: D00PBX
DrugBank: DB11581
 Compound Name MCI-186 Approved [4]
Synonyms
Edarabone; Edaravone; Methylphenylpyrazolone; Monopyrazolone; Norantipyrine; Norphenazone; Phenylmethylpyrazolone; Radicut; Developer Z; Edaravone [INN]; Phenyl methyl pyrazolone; CDS1_000986; CI Developer 1; IN1263; M0687; MCI 186; Edaravone(jan); Radicut (TN); AE-641/00371017; C.I. Developer 1; Edaravone (JAN/INN); (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 1-Phenyl-3-methyl-5-pyrazolone; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 3-Methyl-1-phenyl-2-pyrazoline-5-one; 3-Methyl-1-phenyl-5-pyrazolone; 3-Methyl-1-phenylpyrazol-5-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 5-methyl-2-phenyl-4H-pyrazol-3-one
    Click to Show/Hide
MOA Regulator (upregulator)
External Link
CID: 4021
TTD: D06DLI
DrugBank: DB12243
 Compound Name Taxol Approved [5]
Synonyms
C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-
    Click to Show/Hide
MOA Modulator
External Link
CID: 36314
TTD: D0C4RB
DrugBank: DB01229
 Compound Name Oblimersen Phase 3 [6]
MOA Inhibitor
External Link
CID: 118984457
TTD: D05RJP
 Compound Name RG7601 Phase 3 [3]
MOA Modulator
External Link
TTD: D0I6OI
 Compound Name Taxol/Paraplatin/Herceptin Phase 3 [7]
Synonyms
Paclitaxel/carboplatin/trastuzumab
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0J6PY
 Compound Name ABT-263 Phase 3 [8]
Synonyms
Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki < 0.01 nM
External Link
CID: 24978538
TTD: D06ETI
DrugBank: DB12340
 Compound Name Thymoquinone Phase 2/3 [9]
Synonyms
490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10281
TTD: DY4OZ6
 Compound Name Gossypol Phase 2 [10]
Synonyms
303-45-7; (-)-Gossypol; 90141-22-3; (+)-Gossypol; Pogosin; Tash 1; racemic-Gossypol; (R)-(-)-Gossypol; (R)-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; CCRIS 2689; NSC56817; NSC 56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 20300-26-9; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC624336; Gossypol acetate
    Click to Show/Hide
MOA Regulator
Activity Ki = 170 nM
External Link
CID: 3503
TTD: D0Z0HH
DrugBank: DB13044
 Compound Name PI-88/Taxotere Phase 2 [11]
Synonyms
PI-88/docetaxel
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0K8LB
 Compound Name Obatoclax Phase 2 [12]
Synonyms
CHEMBL408194; UNII-QN4128B52A; QN4128B52A; SCHEMBL631676; SCHEMBL16340850; BDBM50376902; ZINC136873052; DB12191; NCGC00387855-01; BRD-K15600710-066-01-7
    Click to Show/Hide
MOA Inhibitor
Activity EC50 = 300 nM
External Link
CID: 11404337
TTD: D02OZK
DrugBank: DB12191
 Compound Name APG-2575 Phase 1/2 [13]
Synonyms
Bcl-2/Bcl-xl inhibitor 1; 2180923-05-9; OSL3FEZ1IF; UNII-OSL3FEZ1IF; SCHEMBL20580489; US10221174, Compound 6; BDBM361577; HY-129179; CS-0103865; (S)-N-((4-(((1,4-dioxan-2-yl)methyl)amino)-3- nitrophenyl)sulfonyl)-2-((1H-pyrrolo[2,3-b]pyridin- 5-yl)oxy)-4-(4-((6-(4-chlorophenyl)spiro[3.5]non-6- en-7-yl)methyl)piperazin-1-yl)benzamide; Benzamide, 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-1-piperazinyl)-N-((4-(((2S)-1,4-dioxan-2-ylmethyl)amino)-3-nitrophenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 137355972
TTD: D2Y7ZG
 Compound Name APG-1252 Phase 1/2 [14]
MOA Inhibitor
External Link
TTD: D4WN2M
 Compound Name AZD0466 Phase 1/2 [15]
MOA Inhibitor
External Link
TTD: DQ1P6X
 Compound Name BCL201 Phase 1 [16]
MOA Inhibitor
External Link
TTD: D0C6YQ
 Compound Name Pc4 Phase 1 [17]
Synonyms
Pc4 (topical formulation, cancer/psoriasis/dermatological disease) Fluence/CWRU/UHCMC
    Click to Show/Hide
MOA Agonist
External Link
TTD: D0L2YF
 Compound Name BGB-11417 Phase 1 [18]
MOA Inhibitor
External Link
TTD: D74BRK
 Compound Name LP-108 Phase 1 [19]
External Link
TTD: DBY42T
 Compound Name LOXO-338 Phase 1 [20]
MOA Inhibitor
External Link
TTD: DJLX87
 Compound Name VOB560 Phase 1 [21]
Synonyms
S 65487
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: DP63FS
 Compound Name AI-850 Phase 1 [22]
MOA Modulator
External Link
TTD: D03UDW
 Compound Name Irofulven/Taxotere Phase 1 [23]
Synonyms
MGI 114/docetaxel
    Click to Show/Hide
MOA Modulator
External Link
TTD: D05CHN
 Compound Name Indole-based analog 2 Patented [24]
Synonyms
PMID27744724-Compound-16
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 7100 nM
External Link
TTD: D0C2DV
 Compound Name PMID27744724-Compound-10 Patented [24]
MOA Inhibitor
Activity Ki = 5800 nM
External Link
TTD: D0IS8R
 Compound Name PMID27744724-Compound-21 Patented [24]
MOA Inhibitor
Activity Ki = 2000 nM
External Link
TTD: D0J9FN
 Compound Name Indole-based analog 3 Patented [24]
Synonyms
PMID27744724-Compound-17
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 1900 nM
External Link
TTD: D0MZ7I
 Compound Name PMID27744724-Compound-18 Patented [24]
MOA Inhibitor
Activity Ki = 33000 nM
External Link
TTD: D0TU3N
 Compound Name ABT-737 Terminated [25]
Synonyms
852808-04-9; ABT 737; ABT737; UNII-Z5NFR173NV; Z5NFR173NV; 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide; CHEMBL376408; C42H45ClN6O5S2; 4-{4-[(4'-Chlorobiphenyl-2-Yl)methyl]piperazin-1-Yl}-N-{[4-({(1r)-3-(Dimethylamino)-1-[(Phenylthio)methyl]propyl}amino)-3-Nitrophenyl]sulfonyl}benzamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki < 0.6 nM
External Link
CID: 11228183
TTD: D0L8WH
 Compound Name WL-276 Investigative [26]
MOA Modulator
External Link
TTD: D04HAA
 Compound Name N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide Investigative [27]
Synonyms
CHEMBL214965; SCHEMBL15313847
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5000 nM
External Link
CID: 16090304
TTD: D04RTY
 Compound Name 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine Investigative [28]
MOA Inhibitor
Activity IC50 = 1600 nM
External Link
CID: 135468219
TTD: D06AQG
 Compound Name modified HA14-1 compounds (cancer) Investigative [29]
Synonyms
Bcl-2 inhibitor (cancer), GL Pharmaceuticals; HA14-1, GL Pharmaceuticals
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0S0YV
 Compound Name Apogossypol Investigative [30]
Synonyms
BI-79D10; BI-97C1; CNDO-103; CNDO-133
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 640 nM
External Link
CID: 454878
TTD: D0V7PX
 Compound Name 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide Investigative [27]
Synonyms
CHEMBL214839; BDBM50196033
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 7000 nM
External Link
CID: 16090303
TTD: D0X0CS
 Compound Name 4,5-dibenzylbenzene-1,2-diol Investigative [31]
Synonyms
4,5-Dibenzyl-1,2-benzenediol; NSC664154; AC1L8EAW; CHEMBL481409; AC1Q79U2; SCHEMBL18604567; CTK7J8443; BDBM34138; 4,5-dibenzylbenzene-1,2-diol, 9; NSC-664154
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4700 nM
External Link
CID: 379493
TTD: D0D6BH
 Compound Name TW-37 Investigative [27]
Synonyms
877877-35-5; N-[4-(2-tert-Butylphenylsulfonyl)phenyl]-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; tw 37; CHEMBL217354; N-(4-((2-(tert-butyl)phenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-(4-(2-tert-butylphenylsulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-[4-[(2-tert-Butylphenyl)sulfonyl]phenyl]-2,3,4-trihydroxy-5-[(2-isopropylphenyl)methyl]benzamide; N-(4-((2-Tert-Butylphenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-((2-isopropylphenyl)methyl)benzamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 200 nM
External Link
CID: 11455910
TTD: D00LHS
 Compound Name QEDIIRNIARHLAQVGDSMDR Investigative [27]
MOA Inhibitor
External Link
CID: 77280325
TTD: D0S6IW
 Compound Name PNT-2258 Phase 2 [32]
External Link
TTD: D07ACL
 Compound Name Beclanorsen Phase 1/2 [32]
Synonyms
SPC-2004; SPC-2993; SPC-2996; Anti-Bcl-2 (LNA antisense therapy), Santaris
    Click to Show/Hide
External Link
TTD: D00GAM
 Compound Name BP1002 Phase 1 [32]
External Link
TTD: DBPV74
 Compound Name G3139 + Thalidomide Investigative [32]
External Link
CID: 91865905
TTD: D00DDR
 Compound Name G3139 + Irinotecan Investigative [32]
External Link
CID: 91865905
TTD: D05IAN
 Compound Name G3139 + G-CSF Investigative [32]
External Link
CID: 91865905
TTD: D0B0HK
 Compound Name G3139 + Fludarabine Investigative [32]
External Link
CID: 91865905
TTD: D0LM3T
 Compound Name BP-100-1.02 Investigative [32]
Synonyms
Liposomal Bcl-2 (lymphoma/solid tumor), Bio-Path
    Click to Show/Hide
External Link
TTD: D0Q5NZ
 Compound Name G3139 + Paclitaxel Investigative [32]
External Link
CID: 91865905
TTD: D0S1FM
 Compound Name G3139 + Dexamethasone Investigative [32]
External Link
CID: 91865905
TTD: D0W8ZE
 Compound Name G3139 + Dacarbazine Investigative [32]
External Link
CID: 91865905
TTD: D0XU1I
 Compound Name G3139 + cytarabine (ARA-C) Investigative [32]
External Link
CID: 91865905
TTD: D0XU9F
Cysteine methyltransferase DNMT3A (DNMT3A) 8 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name PMID27376512-Compound-Figure3CN Patented [33]
MOA Inhibitor
Activity EC50 = 1100 nM
External Link
CID: 117968550
TTD: D02VTV
 Compound Name PMID27376512-Compound-Figure3CG Patented [33]
MOA Inhibitor
Activity EC50 = 2400 nM
External Link
CID: 117967861
TTD: D03LZO
 Compound Name PMID27376512-Compound-Figure3CM Patented [33]
MOA Inhibitor
Activity EC50 = 1100 nM
External Link
CID: 117976053
TTD: D0F8AB
 Compound Name PMID27376512-Compound-Figure2aExample1 Patented [33]
MOA Inhibitor
Activity IC50 = 3000 nM
External Link
CID: 71521835
TTD: D01LUJ
 Compound Name PMID27376512-Compound-MTC-424 Patented [33]
MOA Inhibitor
Activity IC50 = 1940 nM
External Link
TTD: D02WRM
 Compound Name PMID27376512-Compound-MTC-427 Patented [33]
MOA Inhibitor
Activity IC50 = 295 nM
External Link
TTD: D0HA0J
 Compound Name PMID27376512-Compound-MTC-422 Patented [33]
MOA Inhibitor
Activity IC50 = 1430 nM
External Link
TTD: D0QY0N
 Compound Name PMID27376512-Compound-MTC-423 Patented [33]
MOA Inhibitor
Activity IC50 = 363 nM
External Link
TTD: D0W9VZ
2C10: Pancreatic cancer 182 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Atezolizumab Approved [16]
External Link
TTD: D0YM2K
 Compound Name Trimethadione Approved [34]
Synonyms
Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]
    Click to Show/Hide
External Link
CID: 5576
TTD: D0U4VT
DrugBank: DB00347
 Compound Name Motixafortide Approved [16]
External Link
CID: 91865076
TTD: D0T6CN
DrugBank: DB14939
 Compound Name Uridine triacetate Approved [35]
Synonyms
PN401
    Click to Show/Hide
External Link
CID: 20058
TTD: D0OL7F
DrugBank: DB09144
 Compound Name Bentiromide Approved [36]
Synonyms
Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so
    Click to Show/Hide
External Link
CID: 6957673
TTD: D0L0SW
DrugBank: DB00522
 Compound Name Olaparib Approved [16]
Synonyms
AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
    Click to Show/Hide
External Link
CID: 23725625
TTD: D0J9HW
DrugBank: DB09074
 Compound Name Streptozocin Approved [37]
Synonyms
Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose
    Click to Show/Hide
External Link
CID: 29327
TTD: D0I8RR
DrugBank: DB00428
 Compound Name Plazomicin Phase 3 [38]
Synonyms
ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,
    Click to Show/Hide
External Link
CID: 42613186
TTD: D0E6BB
DrugBank: DB12615
 Compound Name Taxol Approved [16]
Synonyms
C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-
    Click to Show/Hide
External Link
CID: 36314
TTD: D0C4RB
DrugBank: DB01229
 Compound Name Ibrutinib Phase 3 [16]
Synonyms
PCI-32765; Ibrutinib (BTK inhibitor)
    Click to Show/Hide
External Link
CID: 24821094
TTD: D09KTS
DrugBank: DB09053
 Compound Name Erlotinib Approved [39]
Synonyms
Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline
    Click to Show/Hide
External Link
CID: 176870
TTD: D07POC
DrugBank: DB00530
 Compound Name Ruxolitinib Approved [40]
Synonyms
Ruxolitinib (JAK inhibitor)
    Click to Show/Hide
External Link
CID: 25126798
TTD: D04LKS
DrugBank: DB08877
 Compound Name Nivolumab Approved [16]
External Link
TTD: D00GOV
 Compound Name Coenzyme Q10 Phase 2 [16]
Synonyms
CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen
    Click to Show/Hide
External Link
CID: 5281915
TTD: D01ZUA
DrugBank: DB09270
 Compound Name Aglatimagene besadenovec Phase 1/2 [16]
External Link
TTD: DE8H1W
 Compound Name Zolbetuximab Phase 3 [41]
Synonyms
IMAB362
    Click to Show/Hide
External Link
TTD: D4HQ1F
 Compound Name AC-1204 Phase 3 [42]
Synonyms
isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA
    Click to Show/Hide
External Link
CID: 12311031
TTD: D0Y1RN
 Compound Name Radiosensitizer gene therapy Phase 3 [43]
Synonyms
Radiosensitizer gene therapy (prostate cancer)
    Click to Show/Hide
External Link
TTD: D0X4NF
 Compound Name Glufosfomide Phase 3 [44]
External Link
TTD: D0W7PQ
 Compound Name Yttrium (90Y) clivatuzumab tetraxetan Phase 3 [45]
Synonyms
PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4
    Click to Show/Hide
External Link
TTD: D0V2KR
 Compound Name Y-90 Clivatuzumab Phase 3 [46]
External Link
TTD: D0T8AI
 Compound Name Civacir Phase 3 [47]
External Link
TTD: D0P9UP
 Compound Name GV1001 Phase 3 [48]
External Link
TTD: D0N0QC
 Compound Name Masitinib Phase 3 [16]
Synonyms
790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
    Click to Show/Hide
External Link
CID: 10074640
TTD: D0MW0N
DrugBank: DB11526
 Compound Name Glufosfamide Phase 3 [16]
Synonyms
Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol
    Click to Show/Hide
External Link
CID: 123628
TTD: D0L9IA
DrugBank: DB06177
 Compound Name Sapacitabine Phase 3 [16]
Synonyms
CYC682
    Click to Show/Hide
External Link
CID: 153970
TTD: D0D4RF
DrugBank: DB06365
 Compound Name Pelareorep Phase 2 [49]
External Link
TTD: D0BF8Y
 Compound Name Pamrevlumab Phase 3 [50]
External Link
TTD: D09TJJ
 Compound Name GRASPA Phase 1 [51]
Synonyms
L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech
    Click to Show/Hide
External Link
TTD: D09JKS
 Compound Name Pancreas algenpantucel-L Phase 3 [52]
Synonyms
HyperAcute (TN)
    Click to Show/Hide
External Link
TTD: D08PBQ
 Compound Name CPI-613 Phase 3 [53]
Synonyms
95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
    Click to Show/Hide
External Link
CID: 24770514
TTD: D07NVI
DrugBank: DB12109
 Compound Name Zarnestra Phase 3 [6]
Synonyms
JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE
    Click to Show/Hide
External Link
CID: 159324
TTD: D07NPS
DrugBank: DB04960
 Compound Name MM-398 Phase 3 [54]
External Link
CID: 91809656
TTD: D07HOH
 Compound Name Marimastat Phase 3 [55]
Synonyms
Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide
    Click to Show/Hide
External Link
CID: 119031
TTD: D05VZE
DrugBank: DB00786
 Compound Name AM0010 Phase 3 [56]
External Link
TTD: D03MYX
 Compound Name ANX-510 Phase 3 [57]
External Link
CID: 135400185
TTD: D01YKI
 Compound Name Napabucasin Phase 3 [16]
Synonyms
83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919
    Click to Show/Hide
External Link
CID: 10331844
TTD: D01IGZ
DrugBank: DB12155
 Compound Name Algenpantucel-L Phase 3 [58]
Synonyms
HyperAcute pancreas (TN)
    Click to Show/Hide
External Link
TTD: D00HSK
 Compound Name OT-101 Phase 2/3 [16]
External Link
TTD: DO5H6K
 Compound Name RP101 Phase 2/3 [59]
Synonyms
SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,
    Click to Show/Hide
External Link
CID: 446727
TTD: D0Z9LP
DrugBank: DB03312
 Compound Name NLG8189 Phase 2/3 [16]
Synonyms
1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189
    Click to Show/Hide
External Link
CID: 405012
TTD: D0B5HS
DrugBank: DB12827
 Compound Name LY2157299 Phase 2/3 [16]
Synonyms
Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
    Click to Show/Hide
External Link
CID: 10090485
TTD: D06TFI
DrugBank: DB11911
 Compound Name SM-88 Phase 2/3 [60]
External Link
CID: 3125
TTD: D03ZDX
 Compound Name SiG12D-LODER Phase 2 [16]
External Link
TTD: DNH67V
 Compound Name BNT141 Phase 2 [61]
External Link
TTD: DFZ19J
 Compound Name BNT321 Phase 2 [62]
Synonyms
MVT-5873
    Click to Show/Hide
External Link
TTD: D7AOL8
 Compound Name BPM 31510 Phase 2 [63]
External Link
TTD: D4MZR2
 Compound Name GC4711 Phase 2 [64]
Synonyms
UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,
    Click to Show/Hide
External Link
CID: 131634674
TTD: D3P8JK
 Compound Name CYTO-401 Phase 2 [65]
External Link
TTD: D2Q5XO
 Compound Name Zenocutuzumab Phase 2 [66]
External Link
TTD: D1J4CI
 Compound Name Cabiralizumab Phase 2 [16]
External Link
TTD: D0YO4B
 Compound Name VS-6063 Phase 2 [16]
Synonyms
Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu
    Click to Show/Hide
External Link
CID: 25117126
TTD: D0Y1UO
DrugBank: DB12282
 Compound Name MENK Phase 2 [44]
External Link
TTD: D0VG7I
 Compound Name CO-101 Phase 2 [67]
Synonyms
methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester
    Click to Show/Hide
External Link
CID: 9828310
TTD: D0V0CJ
DrugBank: DB12564
 Compound Name MENK Phase 2 [16]
Synonyms
IRT-101
    Click to Show/Hide
External Link
TTD: D0TN1J
 Compound Name TL-118 Phase 2 [68]
Synonyms
Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma
    Click to Show/Hide
External Link
TTD: D0T9OC
 Compound Name Antroquinonol Phase 2 [16]
Synonyms
Hocena; Fungal extract (cancer), Golden Biotechnology
    Click to Show/Hide
External Link
CID: 24875259
TTD: D0T3AW
DrugBank: DB12326
 Compound Name NPC-1C Phase 2 [16]
Synonyms
Ensituximab
    Click to Show/Hide
External Link
TTD: D0T2FC
 Compound Name Necuparanib Phase 2 [69]
External Link
TTD: D0S3CX
 Compound Name CCX872 Phase 2 [16]
External Link
TTD: D0Q3PB
 Compound Name GC4419 Phase 1/2 [16]
Synonyms
Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-
    Click to Show/Hide
External Link
CID: 71587734
TTD: D0PV9N
 Compound Name Istiratumab Phase 2 [49]
External Link
TTD: D0P4ZR
 Compound Name GI-4000 Phase 2 [70]
External Link
TTD: D0N4SF
 Compound Name OCV-101 Phase 2 [71]
Synonyms
OTS-11101
    Click to Show/Hide
External Link
TTD: D0LX8Z
 Compound Name RX-3117 Phase 2 [16]
Synonyms
Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva
    Click to Show/Hide
External Link
CID: 11242315
TTD: D0L7WS
 Compound Name Ensitiximab Phase 2 [44]
External Link
TTD: D0KL4T
 Compound Name GI-4000 + gemcitabine Phase 2 [72]
External Link
TTD: D0KK9V
 Compound Name BC-819 Phase 2 [73]
External Link
TTD: D0K0KQ
 Compound Name IRT-102 Phase 2 [74]
External Link
CID: 42785
TTD: D0J5UK
 Compound Name LE-DT Phase 2 [75]
Synonyms
Liposomal docetaxel
    Click to Show/Hide
External Link
TTD: D0J2NX
 Compound Name TH-302 Phase 2 [16]
Synonyms
evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174
    Click to Show/Hide
External Link
CID: 11984561
TTD: D0H1EA
DrugBank: DB06091
 Compound Name Demcizumab Phase 2 [44]
External Link
TTD: D0GJ7N
 Compound Name Anti-PSCA mab Phase 2 [76]
External Link
TTD: D0G7ZT
 Compound Name ALT-803 Phase 2 [49]
Synonyms
IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience
    Click to Show/Hide
External Link
TTD: D0FD7H
 Compound Name ARQ 761 Phase 2 [16]
External Link
TTD: D0DR0P
 Compound Name Reolysinpelareorep Phase 2 [16]
External Link
TTD: D0CW2N
 Compound Name PBI-05204 Phase 2 [16]
External Link
CID: 11541511
TTD: D0A4YK
DrugBank: DB12843
 Compound Name PCI-27483 Phase 2 [77]
External Link
CID: 135425273
TTD: D09TFL
DrugBank: DB13000
 Compound Name RX-0201 Phase 2 [44]
External Link
TTD: D07SYZ
 Compound Name CP-613 Phase 2 [78]
External Link
TTD: D07FXF
 Compound Name CART 19 Preclinical [79]
External Link
TTD: D06TKR
 Compound Name VT-122 Phase 1 [44]
External Link
TTD: D05VKS
 Compound Name PEGPH20 Phase 2 [80]
External Link
TTD: D05INV
 Compound Name Ficlatuzumab Phase 2 [16]
Synonyms
AV-299
    Click to Show/Hide
External Link
TTD: D03UBW
 Compound Name Tigatuzumab Phase 2 [81]
External Link
TTD: D03LTO
 Compound Name CRS-207 Phase 2 [82]
External Link
TTD: D02WSB
 Compound Name CAP1-6D Phase 2 [83]
Synonyms
Modified CEA peptide (pancreatic cancer), University of Chicago
    Click to Show/Hide
External Link
CID: 396060
TTD: D02UKX
 Compound Name SGT-53 Phase 2 [16]
Synonyms
P53 gene stimulator (solid tumor), Synergene Therapeutics
    Click to Show/Hide
External Link
TTD: D02EOH
 Compound Name Tarextumab Phase 2 [84]
External Link
TTD: D01QLP
 Compound Name BVD-523 Phase 2 [16]
External Link
CID: 11719003
TTD: D01IED
DrugBank: DB13930
 Compound Name Ocaperidone Phase 2 [49]
Synonyms
Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019
    Click to Show/Hide
External Link
CID: 71351
TTD: D01FQR
DrugBank: DB06229
 Compound Name Encapsulated live cells converting ifosfamide Phase 2 [16]
External Link
TTD: D01DLT
 Compound Name LY2603618 Phase 2 [85]
Synonyms
Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618 IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea
    Click to Show/Hide
External Link
CID: 11955855
TTD: D00NZL
DrugBank: DB11662
 Compound Name Salirasib Discontinued in Phase 1/2 [86]
Synonyms
162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032
    Click to Show/Hide
External Link
CID: 5469318
TTD: D00KTV
DrugBank: DB12681
 Compound Name MM-141 Phase 2 [16]
External Link
TTD: D00BUO
 Compound Name GB1275 Phase 1/2 [87]
External Link
TTD: DZ5K6F
 Compound Name ABTL0812 Phase 1/2 [88]
Synonyms
(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ
    Click to Show/Hide
External Link
CID: 21158511
TTD: DMBQ10
 Compound Name GP-2250 Phase 1/2 [89]
External Link
TTD: DARV32
 Compound Name Delolimogene mupadenorepvec Phase 1/2 [90]
Synonyms
LOAd703
    Click to Show/Hide
External Link
TTD: D5V7XP
 Compound Name GSK3145095 Phase 1/2 [91]
Synonyms
1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)
    Click to Show/Hide
External Link
CID: 118557502
TTD: D0Z7BX
 Compound Name Encapsulated cell therapy Phase 1/2 [92]
External Link
TTD: D0XY8C
 Compound Name ETBX-011 cancer vaccine Phase 1/2 [70]
External Link
TTD: D0U1WU
 Compound Name BPX-601 Phase 1/2 [93]
External Link
TTD: D0TY6U
 Compound Name NANT Phase 1/2 [16]
External Link
TTD: D0T4GG
 Compound Name BrevaRex Phase 1/2 [94]
Synonyms
BrevaRex MAb; monoclonal antibody
    Click to Show/Hide
External Link
TTD: D0M5JC
 Compound Name DCVax-Pancreas Phase 1/2 [95]
Synonyms
Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics
    Click to Show/Hide
External Link
TTD: D0L7LT
 Compound Name PEGylated hyaluronidase (human recombinant) Phase 1/2 [96]
Synonyms
PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme
    Click to Show/Hide
External Link
TTD: D0L5IA
 Compound Name CAR-T cells targeting mesothelin Phase 1/2 [97]
External Link
TTD: D0KC2S
 Compound Name MALP-2S Phase 1/2 [98]
External Link
TTD: D0K3SM
 Compound Name Anti-Mesothelin CAR-T cells Phase 1/2 [99]
External Link
TTD: D0BE6M
 Compound Name Anti-MUC1 CAR T Cells Phase 1/2 [100]
External Link
TTD: D08WII
 Compound Name Anti-HER2 CAR-T Phase 1/2 [101]
External Link
TTD: D08QZH
 Compound Name CAR-T Cells targeting EpCAM Phase 1/2 [102]
External Link
TTD: D08QYW
 Compound Name Anti-MUC1 AR20.5 Phase 1/2 [49]
External Link
TTD: D07YGQ
 Compound Name AR20.5 Phase 1/2 [16]
External Link
TTD: D07PCZ
 Compound Name G0-203-2c Phase 1/2 [103]
External Link
TTD: D04WHM
 Compound Name LOAd703 Phase 1/2 [16]
External Link
TTD: D03ZIP
 Compound Name Anti-mesothelin CAR transduced PBL Phase 1/2 [104]
External Link
TTD: D00YXG
 Compound Name M9241 Phase 1 [105]
Synonyms
NHS-IL12
    Click to Show/Hide
External Link
TTD: DO8W9E
 Compound Name NBF-006 Phase 1 [106]
External Link
TTD: D8UZ5R
 Compound Name AB680 Phase 1 [107]
Synonyms
AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH
    Click to Show/Hide
External Link
CID: 130205852
TTD: D7CE6N
 Compound Name STAT400 Phase 1 [108]
External Link
TTD: D75WVO
 Compound Name CEND-1 Phase 1 [109]
Synonyms
iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide
    Click to Show/Hide
External Link
CID: 134611625
TTD: D5WU7B
 Compound Name CAR-T Cells targeting EGFRvIII Phase 1 [110]
External Link
TTD: D0ZQ6N
 Compound Name HuCART-meso cells Phase 1 [111]
External Link
TTD: D0ZF9J
 Compound Name OCV-105 Phase 1 [112]
Synonyms
Cancer vaccine (pancreas), Otsuka/OncoTherapy
    Click to Show/Hide
External Link
TTD: D0X9YB
 Compound Name SBP-101 Phase 1 [44]
Synonyms
diethyl dihydroxyhomospermine
    Click to Show/Hide
External Link
TTD: D0VE9F
 Compound Name RG7882 Phase 1 [49]
External Link
TTD: D0V7QW
 Compound Name CART-meso-19 T cells Phase 1 [113]
External Link
TTD: D0V5DD
 Compound Name MOv19-BBz CAR T cells Phase 1 [114]
External Link
TTD: D0T7CR
 Compound Name Anti-MUC1 AR20.5 mab Phase 1 [115]
External Link
TTD: D0S3AE
 Compound Name Anti-CEA-CAR T Phase 1 [116]
External Link
TTD: D0S1QN
 Compound Name MVT-5873 Phase 1 [49]
External Link
TTD: D0Q5QV
 Compound Name CART-meso cells Phase 1 [117]
External Link
TTD: D0P2GA
 Compound Name CAR-20/19-T Cells Phase 1 [118]
External Link
TTD: D0NU9L
 Compound Name CARTmeso/19 Phase 1 [119]
External Link
TTD: D0MD8S
 Compound Name CAR-T Cells targeting Mesothelin Phase 1 [110]
External Link
TTD: D0L7OJ
 Compound Name CAR-T Cells targeting CEA Phase 1 [110]
External Link
TTD: D0L6HU
 Compound Name HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine Phase 1 [120]
Synonyms
HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)
    Click to Show/Hide
External Link
TTD: D0K6UQ
 Compound Name Anti-hCD70 CAR transduced PBL Phase 1 [121]
External Link
TTD: D0JO9M
 Compound Name MORAb-066 Phase 1 [122]
Synonyms
Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek
    Click to Show/Hide
External Link
TTD: D0H8PX
 Compound Name Anti-MUC1 mab Phase 1 [123]
External Link
TTD: D0H2CF
 Compound Name Anti-meso-CAR vector transduced T cells Phase 1 [124]
External Link
TTD: D0G4GY
 Compound Name CRS-207 + GVAX Phase 2 [44]
External Link
TTD: D0EY1Y
 Compound Name Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1 Phase 1 [125]
External Link
TTD: D0EB0Y
 Compound Name Meso-CART Phase 1 [126]
External Link
TTD: D0D2LE
 Compound Name ASG-5ME Phase 1 [127]
External Link
TTD: D0BC6M
 Compound Name Anti-CD133-CAR vector-transduced T cells Phase 1 [128]
External Link
TTD: D09HRH
 Compound Name IRX4204 Phase 1 [16]
Synonyms
220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid
    Click to Show/Hide
External Link
CID: 9863341
TTD: D09DJC
DrugBank: DB11806
 Compound Name AbGn-107 Phase 1 [16]
External Link
TTD: D08GZE
 Compound Name LMB-100 Phase 1/2 [16]
External Link
TTD: D07RDQ
 Compound Name PLX7486 Phase 1 [129]
External Link
TTD: D07PSL
 Compound Name CAR-T Cells targeting HER2 Phase 1 [110]
External Link
TTD: D06XWD
 Compound Name CAR-T Cells targeting MUCI Phase 1 [110]
External Link
TTD: D06URX
 Compound Name SEL-403 Phase 1 [16]
External Link
TTD: D03ZLN
 Compound Name CAR-T Cells targeting PSCA Phase 1 [110]
External Link
TTD: D02MYI
 Compound Name Anti-CEA CAR-T cells Phase 1 [130]
External Link
TTD: D00KDQ
 Compound Name MVT-1075 Phase 1 [16]
External Link
TTD: D00IFQ
 Compound Name CAR-CLD18 T cell Clinical trial [131]
External Link
TTD: D06CWZ
 Compound Name CART-meso cells Clinical trial [132]
External Link
TTD: D04WZL
 Compound Name PMID28460551-Compound-1 Patented [133]
External Link
CID: 25190990
TTD: D0IH3I
DrugBank: DB14866
 Compound Name Tanomastat Discontinued in Phase 3 [134]
Synonyms
Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid
    Click to Show/Hide
External Link
CID: 6918336
TTD: D0Q1CD
DrugBank: DB06276
 Compound Name Larotaxel Discontinued in Phase 3 [135]
Synonyms
Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881
    Click to Show/Hide
External Link
CID: 6918260
TTD: D0J0RV
DrugBank: DB12984
 Compound Name Apricoxib Discontinued in Phase 2 [136]
Synonyms
TG01
    Click to Show/Hide
External Link
CID: 9820073
TTD: D0S7IZ
DrugBank: DB12378
 Compound Name Lintitript Discontinued in Phase 2 [137]
Synonyms
SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid
    Click to Show/Hide
External Link
CID: 122077
TTD: D01ZXW
DrugBank: DB04867
 Compound Name Merbarone Discontinued in Phase 2 [138]
Synonyms
NSC-336628
    Click to Show/Hide
External Link
CID: 4990817
TTD: D00VZF
 Compound Name LY293111 Discontinued in Phase 2 [139]
Synonyms
Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny
    Click to Show/Hide
External Link
CID: 177941
TTD: D00GNK
DrugBank: DB12850
 Compound Name HMN-214 Discontinued in Phase 1 [140]
Synonyms
N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide
    Click to Show/Hide
External Link
CID: 9888590
TTD: D0R7ID
 Compound Name RG7600 Discontinued in Phase 1 [141]
External Link
TTD: D04TYP
 Compound Name IC261 Preclinical [142]
Synonyms
IC-261; IC 261
    Click to Show/Hide
External Link
CID: 5288600
TTD: D0UN8H
DrugBank: DB03083
 Compound Name ANAVEX 1007 Preclinical [143]
External Link
TTD: D0M6OW
 Compound Name IPH-4201 Terminated [144]
Synonyms
MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM
    Click to Show/Hide
External Link
TTD: D0F6HW
 Compound Name MesoTarg Investigative [145]
External Link
TTD: D0W5KO
 Compound Name PAT-PM-1 Investigative [145]
Synonyms
PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys
    Click to Show/Hide
External Link
TTD: D0U9YV
 Compound Name OP-04 Investigative [145]
Synonyms
OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon
    Click to Show/Hide
External Link
TTD: D0S0DY
 Compound Name VLI-27 Investigative [146]
Synonyms
AKT inhibitor (pancreatic cancer), NovaLead Pharma
    Click to Show/Hide
External Link
TTD: D0N7CY
 Compound Name GS-326 Investigative [145]
Synonyms
GS-326C
    Click to Show/Hide
External Link
CID: 3041004
TTD: D0LI3A
 Compound Name PX-12 Phase 2 [147]
External Link
CID: 219104
TTD: D0FT8G
DrugBank: DB05448
 Compound Name Prodigiosin Investigative [145]
External Link
CID: 135455579
TTD: D06YEE
 Compound Name Pbi-shPDX-1 LP Investigative [145]
External Link
TTD: D02FAI
 Compound Name Gastrin 17C diphtheria toxoid conjugate Investigative [145]
Synonyms
Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)
    Click to Show/Hide
External Link
TTD: D01PNR
 Compound Name HS-P1 Investigative [145]
Synonyms
HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics
    Click to Show/Hide
External Link
CID: 71537
TTD: D00JKJ
References
Ref 1 Excessive miR-25-3p maturation via N(6)-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Nat Commun. 2019 Apr 23;10(1):1858. doi: 10.1038/s41467-019-09712-x.
Ref 2 Celastrol suppresses human pancreatic cancer via m(6)A-YTHDF3-mediated downregulation of Claspin and Bcl-2. Discov Oncol. 2023 Dec 18;14(1):233. doi: 10.1007/s12672-023-00838-5.
Ref 3 ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6.
Ref 4 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
Ref 5 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
Ref 6 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278.
Ref 7 Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32. doi: 10.3816/CBC.2005.n.047.
Ref 8 Clinical pipeline report, company report or official report of Roche (2009).
Ref 9 Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. doi: 10.1016/j.drudis.2020.04.023. Epub 2020 May 7.
Ref 10 Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
Ref 11 Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010 Jun;21(6):1302-1307. doi: 10.1093/annonc/mdp524. Epub 2009 Nov 16.
Ref 12 Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9. doi: 10.3816/CLML.2010.n.059.
Ref 13 A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma. Oncol Res. 2020 Sep 1;28(4):331-344. doi: 10.3727/096504020X15825405463920. Epub 2020 Feb 24.
Ref 14 Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206. doi: 10.1002/cam4.3090. Epub 2020 Apr 28.
Ref 15 Design and optimisation of dendrimer-conjugated Bcl-2/x(L) inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021 Jan 25;4(1):112. doi: 10.1038/s42003-020-01631-8.
Ref 16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 17 Association between the photodynamic loss of Bcl-2 and the sensitivity to apoptosis caused by phthalocyanine photodynamic therapy. Photochem Photobiol. 2003 Jul;78(1):1-8.
Ref 18 Clinical pipeline report, company report or official report of BeiGene.
Ref 19 National Cancer Institute Drug Dictionary (drug name LP-108).
Ref 20 ClinicalTrials.gov (NCT05024045) A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies. U.S.National Institutes of Health.
Ref 21 Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer. Cells. 2020 May 21;9(5):1287. doi: 10.3390/cells9051287.
Ref 22 Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res. 2005 Mar;22(3):347-55. doi: 10.1007/s11095-004-1871-1.
Ref 23 Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. Prostate. 2004 Apr 1;59(1):22-32. doi: 10.1002/pros.10351.
Ref 24 Mcl-1 inhibitors: a patent review. Expert Opin Ther Pat. 2017 Feb;27(2):163-178. doi: 10.1080/13543776.2017.1249848. Epub 2016 Nov 17.
Ref 25 Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem. 2007 Feb 22;50(4):641-62.
Ref 26 WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth. Cancer Res. 2008 Jun 1;68(11):4377-83. doi: 10.1158/0008-5472.CAN-07-6590.
Ref 27 Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42. doi: 10.1021/jm060460o.
Ref 28 Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem. 2001 Dec 6;44(25):4313-24. doi: 10.1021/jm010016f.
Ref 29 The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. Mol Cancer Ther. 2004 Dec;3(12):1513-24.
Ref 30 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7920).
Ref 31 Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention. J Med Chem. 2010 May 27;53(10):3899-906. doi: 10.1021/jm901446n.
Ref 32 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.
Ref 33 DNA methyltransferase inhibitors: an updated patent review (2012-2015). Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. doi: 10.1080/13543776.2016.1209488. Epub 2016 Jul 18.
Ref 34 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7316).
Ref 35 ClinicalTrials.gov (NCT02110147) Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria. U.S. National Institutes of Health.
Ref 36 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 37 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
Ref 38 ClinicalTrials.gov (NCT01970371) A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE). U.S. National Institutes of Health.
Ref 39 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4920).
Ref 40 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5688).
Ref 41 ClinicalTrials.gov (NCT03816163) A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
Ref 42 ClinicalTrials.gov (NCT01741194) AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext. U.S. National Institutes of Health.
Ref 43 Clinical pipeline report, company report or official report of Advantagene.
Ref 44 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 45 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8087).
Ref 46 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018609)
Ref 47 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004347)
Ref 48 ClinicalTrials.gov (NCT01579188) Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 49 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 50 Clinical pipeline report, company report or official report of Fibrogen.
Ref 51 ClinicalTrials.gov (NCT01523808) Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer. U.S. National Institutes of Health.
Ref 52 ClinicalTrials.gov (NCT01072981) Immunotherapy Study for Surgically Resected Pancreatic Cancer. U.S. National Institutes of Health.
Ref 53 ClinicalTrials.gov (NCT03504423) Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas. U.S. National Institutes of Health.
Ref 54 ClinicalTrials.gov (NCT01494506) Study of MM-398 With or Without 5-Fluorouracil and Leucovorin, Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
Ref 55 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5220).
Ref 56 ClinicalTrials.gov (NCT02923921) Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (Sequoia). U.S. National Institutes of Health.
Ref 57 ClinicalTrials.gov (NCT00337389) Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.. U.S. National Institutes of Health.
Ref 58 ClinicalTrials.gov (NCT01836432) Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer. U.S. National Institutes of Health.
Ref 59 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020300)
Ref 60 ClinicalTrials.gov (NCT03512756) A Randomized Phase 2/3 Multi-Center Study of SM-88 in Patients With Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
Ref 61 ClinicalTrials.gov (NCT04683939) Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors. U.S.National Institutes of Health.
Ref 62 ClinicalTrials.gov (NCT03801915) Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers. U.S. National Institutes of Health.
Ref 63 ClinicalTrials.gov (NCT02650804) A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients. U.S.National Institutes of Health.
Ref 64 ClinicalTrials.gov (NCT04698915) Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer. U.S. National Institutes of Health.
Ref 65 Clinical pipeline report, company report or official report of Cytocom
Ref 66 ClinicalTrials.gov (NCT02912949) A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy). U.S.National Institutes of Health.
Ref 67 ClinicalTrials.gov (NCT01233375) Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
Ref 68 ClinicalTrials.gov (NCT01659502) Investigator's Initiated Phase II Study for Pancreatic Cancer Patients. U.S. National Institutes of Health.
Ref 69 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022260)
Ref 70 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 71 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031248)
Ref 72 Clinical pipeline report, company report or official report of GlobeImmune.
Ref 73 ClinicalTrials.gov (NCT01413087) Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
Ref 74 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004141)
Ref 75 ClinicalTrials.gov (NCT01186731) Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
Ref 76 ClinicalTrials.gov (NCT01608711) A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002. U.S. National Institutes of Health.
Ref 77 ClinicalTrials.gov (NCT01020006) Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine. U.S. National Institutes of Health.
Ref 78 Clinical pipeline report, company report or official report of Cornerstone pharmaceuticals.
Ref 79 ClinicalTrials.gov (NCT02640209) Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
Ref 80 ClinicalTrials.gov (NCT01839487) PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer. U.S. National Institutes of Health.
Ref 81 ClinicalTrials.gov (NCT01307891) Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer. U.S. National Institutes of Health.
Ref 82 ClinicalTrials.gov (NCT02243371) GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab. U.S. National Institutes of Health.
Ref 83 ClinicalTrials.gov (NCT00203892) Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
Ref 84 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8453).
Ref 85 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7960).
Ref 86 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026972)
Ref 87 ClinicalTrials.gov (NCT04060342) GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
Ref 88 ClinicalTrials.gov (NCT04431258) A Phase I Open Label Followed by a Phase II Randomized, Controlled Study to Assess the Efficacy and Safety of ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic. U.S.National Institutes of Health.
Ref 89 ClinicalTrials.gov (NCT03854110) Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine. U.S. National Institutes of Health.
Ref 90 ClinicalTrials.gov (NCT02705196) Phase I/IIa Trial Evaluating Safety of LOAd703, an Armed Oncolytic Adenovirus for Pancreatic Cancer. U.S.National Institutes of Health.
Ref 91 ClinicalTrials.gov (NCT03681951) First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 92 VC-01's Path to the Clinic. Viacyte. 2015.
Ref 93 ClinicalTrials.gov (NCT02744287) Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
Ref 94 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010209)
Ref 95 Clinical pipeline report, company report or official report of Northwest BioTherapeutics.
Ref 96 ClinicalTrials.gov (NCT02346370) A Phase 1b/2, Study of Pegylated Recombinant Human Hyaluronidase Combined With Docetaxel Versus Docetaxel Alone in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC.. U.S. National Institutes of Health.
Ref 97 ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
Ref 98 Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase ... Br J Cancer. 2007 Sep 3;97(5):598-604.
Ref 99 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Ref 100 ClinicalTrials.gov (NCT02587689) Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
Ref 101 ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Ref 102 ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
Ref 103 ClinicalTrials.gov (NCT02204085) A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 104 ClinicalTrials.gov (NCT01583686) CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Ref 105 ClinicalTrials.gov (NCT04327986) Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer. U.S. National Institutes of Health.
Ref 106 ClinicalTrials.gov (NCT03819387) A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer. U.S. National Institutes of Health.
Ref 107 ClinicalTrials.gov (NCT04104672) A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies. U.S. National Institutes of Health.
Ref 108 Clinical pipeline report, company report or official report of Statera Biopharma
Ref 109 ClinicalTrials.gov (NCT03517176) CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
Ref 110 ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
Ref 111 ClinicalTrials.gov (NCT03323944) CAR T Cell Immunotherapy for Pancreatic Cancer
Ref 112 Clinical pipeline report, company report or official report of Otsuka Pharmaceutical Co Ltd.
Ref 113 ClinicalTrials.gov (NCT02465983) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
Ref 114 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 115 Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol. 2004 Dec;15(12):1825-33.
Ref 116 ClinicalTrials.gov (NCT02349724) A Clinical Research of CAR T Cells Targeting CEA Positive Cancer
Ref 117 ClinicalTrials.gov (NCT02159716) CART-meso in Mesothelin Expressing Cancers
Ref 118 ClinicalTrials.gov (NCT03375619) Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells
Ref 119 ClinicalTrials.gov (NCT03497819) Autologous CARTmeso/19 Against Pancreatic Cancer
Ref 120 Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer. Int J Oncol. 2014 Mar;44(3):662-8.
Ref 121 ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Ref 122 ClinicalTrials.gov (NCT01761240) Dose Escalation Study MORAb-066 Targeting TF-expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC. U.S. National Institutes of Health.
Ref 123 Clinical pipeline report, company report or official report of Quest PharmaTech.
Ref 124 ClinicalTrials.gov (NCT02580747) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
Ref 125 ClinicalTrials.gov (NCT01897415) Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer
Ref 126 ClinicalTrials.gov (NCT02706782) A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma
Ref 127 2011 Pipeline of Seattle Genetics.
Ref 128 ClinicalTrials.gov (NCT02541370) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
Ref 129 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038879)
Ref 130 ClinicalTrials.gov (NCT03682744) CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Ref 131 ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
Ref 132 ClinicalTrials.gov (NCT03638193) Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
Ref 133 Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015). Expert Opin Ther Pat. 2017 Jul;27(7):753-761. doi: 10.1080/13543776.2017.1325465. Epub 2017 May 5.
Ref 134 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6468).
Ref 135 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010227)
Ref 136 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026002)
Ref 137 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 890).
Ref 138 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000894)
Ref 139 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2948).
Ref 140 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010558)
Ref 141 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035599)
Ref 142 Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
Ref 143 2011 Pipeline of Anavex.
Ref 144 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017007)
Ref 145 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 146 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
Ref 147 A Randomized Phase II Study of PX-12, an Inhibitor of Thioredoxin in Patients With Advanced Cancer of the Pancreas Following Progression After a Gemcitabine-Containing Combination. Cancer Chemother Pharmacol. 2011 Mar;67(3):503-9.